1-8 of 8
Akio Mizutani
Close
Sort by
Journal Articles

A First-in-Human Phase I Study of CTX-712 in Patients with Advanced, Relapsed or Refractory Malignant Tumors - Hematologic Malignancies Dose Escalation Cohort

Hisayuki Yokoyama, Koji Ando, Noriko Fukuhara, Hiroatsu Iida, Suguru Fukuhara, Hiroshi Miyake, Yasushi Tanoue, Maki Yamamoto, Hirokazu Tozaki, Akio Mizutani, Daisuke Morishita, Kunihiko Takeyama, Toshio Shimizu, Noboru Yamamoto
Journal: Blood
Blood (2022) 140 (Supplement 1): 6211–6212.
https://doi.org/10.1182/blood-2022-157241
Published: 2022
Journal Articles

Preclinical Translational Research Suggests a Clinical Trial Strategy for a Novel MALT1 Inhibitor ONO-7018/CTX-177 Against Malignant Lymphomas

Daisuke Morishita, Akio Mizutani, Hiroko Yamakawa, Yasuyoshi Arikawa, Hirokazu Tozaki, Takuro Kameda, Ayako Kamiunten, Keisuke Kataoka, Akinori Yoda, Yotaro Ochi, Kotaro Shide, Koji Izutsu, Yosuke Minami, Kazuya Shimoda, Seishi Ogawa
Journal: Blood
Blood (2022) 140 (Supplement 1): 8874–8875.
https://doi.org/10.1182/blood-2022-171019
Published: 2022
Journal Articles

CTX-712, a Novel Splicing Modulator Targeting Myeloid Neoplasms

Akinori Yoda, Daisuke Morishita, Yotaro Ochi, Akio Mizutani, Takuto Mori, June Takeda, Hirokazu Tozaki, Yoshihiko Satoh, Yasuhito Nannya, Hideki Makishima, Hiroshi Miyake, Seishi Ogawa
Journal: Blood
Blood (2022) 140 (Supplement 1): 489–490.
https://doi.org/10.1182/blood-2022-159338
Published: 2022
Journal Articles

CTX-712, a Novel Clk Inhibitor Targeting Myeloid Neoplasms with SRSF2 Mutation

Akinori Yoda, Daisuke Morishita, Yotaro Ochi, Akio Mizutani, June Takeda, Hirokazu Tozaki, Yoshihiko Satoh, Yasuhito Nannya, Hideki Makishima, Hiroshi Miyake, Seishi Ogawa
Journal: Blood
Blood (2021) 138 (Supplement 1): 205.
https://doi.org/10.1182/blood-2021-148205
Published: 2021
Journal Articles

Preclinical Evaluation of a Novel MALT1 Inhibitor CTX-177 for Relapse/Refractory Lymphomas

Daisuke Morishita, PhD, Akio Mizutani, PhD, Hirokazu Tozaki, PhD, Yasuyoshi Arikawa, PhD, Takuro Kameda, MD PhD, Ayako Kamiunten, MD, Keisuke Kataoka, MD PhD, Akinori Yoda, PhD, Yotaro Ochi, MD, Kotaro Shide, MD PhD, Koji Izutsu, MD PhD, Yosuke Minami, MDPhD, Kazuya Shimoda, MD PhD, Hiroshi Miyake, PhD, Seishi Ogawa, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–4.
https://doi.org/10.1182/blood-2020-141824
Published: 2020
Journal Articles

CTX-712, a Novel Clk Inhibitor Targeting Myeloid Neoplasms with SRSF2 Mutation

Akinori Yoda, PhD, Daisuke Morishita, PhD, Akio Mizutani, PhD, Yoshihiko Satoh, PhD, Yotaro Ochi, MD, Yasuhito Nannya, MD PhD, Hideki Makishima, MD PhD, Hiroshi Miyake, PhD, Seishi Ogawa, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 404.
https://doi.org/10.1182/blood-2019-131559
Published: 2019
Journal Articles

Antithrombin reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation through promotion of prostacyclin production

Akio Mizutani, Kenji Okajima, Mitsuhiro Uchiba, Hirotaka Isobe, Naoaki Harada, Sachiko Mizutani, Takayuki Noguchi
Journal: Blood
Blood (2003) 101 (8): 3029–3036.
https://doi.org/10.1182/blood-2002-08-2406
Published: 2003
Journal Articles

Activated protein C reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation

Akio Mizutani, Kenji Okajima, Mitsuhiro Uchiba, Takayuki Noguchi
Journal: Blood
Blood (2000) 95 (12): 3781–3787.
https://doi.org/10.1182/blood.V95.12.3781
Published: 2000